Targeting tumor hypoxia with hypoxia-activated prodrugs

Affiliations

¹ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC wykim@med.unc.edu.

Comment

Jen Jen Yeh et al. J Clin Oncol. 2015.

. 2015 May 1;33(13):1505-8.

doi: 10.1200/JCO.2014.60.0759. Epub 2015 Mar 23.

¹ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC wykim@med.unc.edu.

No abstract available

Comment on

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP. Borad MJ, et al. J Clin Oncol. 2015 May 1;33(13):1475-81. doi: 10.1200/JCO.2014.55.7504. Epub 2014 Dec 15. J Clin Oncol. 2015. PMID: 25512461 Free PMC article. Clinical Trial.